Published in Blood Weekly, August 26th, 2004
The study enrolled 12 patients with type I Gaucher disease from several countries. TKT expects to release top-line data in the second half of 2005.
Lead investigator of the study, Ari Zimran, Shaare Zedek Medical Center, Jerusalem, Israel, stated, "I am honored and excited to lead the first Gaucher study evaluating an alternative enzyme replacement therapy for Gaucher patients. Since this therapeutic protein is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.